Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

LIGAND PHARMACEUTICALS INC Director's Dealing 2022

Dec 2, 2022

31289_dirs_2022-12-01_803e8d0a-e2f6-4b8a-b019-d6d69422957e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2022-11-30

Reporting Person: Korenberg Matthew E (President & COO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-11-30 Common Stock F 3593 $72.90 Disposed 82428 Direct